AU2003273726B8 - Method of producing recombinant proteins in the mammary gland of non-transgenic mammals - Google Patents
Method of producing recombinant proteins in the mammary gland of non-transgenic mammals Download PDFInfo
- Publication number
- AU2003273726B8 AU2003273726B8 AU2003273726A AU2003273726A AU2003273726B8 AU 2003273726 B8 AU2003273726 B8 AU 2003273726B8 AU 2003273726 A AU2003273726 A AU 2003273726A AU 2003273726 A AU2003273726 A AU 2003273726A AU 2003273726 B8 AU2003273726 B8 AU 2003273726B8
- Authority
- AU
- Australia
- Prior art keywords
- milk
- mammary gland
- infusion
- proteins
- adenoviral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000005075 mammary gland Anatomy 0.000 title claims description 35
- 238000000034 method Methods 0.000 title claims description 29
- 241000124008 Mammalia Species 0.000 title claims description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title description 13
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title description 13
- 230000009261 transgenic effect Effects 0.000 title description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 98
- 239000013598 vector Substances 0.000 claims description 68
- 102000004169 proteins and genes Human genes 0.000 claims description 63
- 235000013336 milk Nutrition 0.000 claims description 57
- 239000008267 milk Substances 0.000 claims description 57
- 210000004080 milk Anatomy 0.000 claims description 57
- 238000001802 infusion Methods 0.000 claims description 31
- 241000701161 unidentified adenovirus Species 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 25
- 230000003612 virological effect Effects 0.000 claims description 18
- 230000006651 lactation Effects 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 8
- 230000009466 transformation Effects 0.000 claims description 8
- 230000006698 induction Effects 0.000 claims description 6
- 102000003951 Erythropoietin Human genes 0.000 claims description 5
- 108090000394 Erythropoietin Proteins 0.000 claims description 5
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 5
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 5
- 239000000854 Human Growth Hormone Substances 0.000 claims description 5
- 229940105423 erythropoietin Drugs 0.000 claims description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 5
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 210000001703 glandular epithelial cell Anatomy 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 2
- 101800004937 Protein C Proteins 0.000 claims description 2
- 102000017975 Protein C Human genes 0.000 claims description 2
- 101800001700 Saposin-D Proteins 0.000 claims description 2
- 102000013275 Somatomedins Human genes 0.000 claims description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims description 2
- 229940116977 epidermal growth factor Drugs 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 229940100601 interleukin-6 Drugs 0.000 claims description 2
- 229940053128 nerve growth factor Drugs 0.000 claims description 2
- 229960000856 protein c Drugs 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 239000000225 tumor suppressor protein Substances 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- -1 antibodies Proteins 0.000 claims 3
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 claims 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 102400001368 Epidermal growth factor Human genes 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 101150080074 TP53 gene Proteins 0.000 claims 1
- 239000003114 blood coagulation factor Substances 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 55
- 230000014509 gene expression Effects 0.000 description 39
- 241001465754 Metazoa Species 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- 241000283707 Capra Species 0.000 description 14
- 238000012546 transfer Methods 0.000 description 12
- 230000001419 dependent effect Effects 0.000 description 9
- 210000002919 epithelial cell Anatomy 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229960000074 biopharmaceutical Drugs 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 210000000481 breast Anatomy 0.000 description 7
- 210000002445 nipple Anatomy 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 102000011632 Caseins Human genes 0.000 description 6
- 108010076119 Caseins Proteins 0.000 description 6
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000005862 Whey Substances 0.000 description 5
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 108010046377 Whey Proteins Proteins 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 4
- 241000282849 Ruminantia Species 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000023247 mammary gland development Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 229940021722 caseins Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 2
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 108060003196 globin Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 102000044890 human EPO Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000035938 sexual maturation Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 101100095844 Mesobuthus martensii KIM2 gene Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100532016 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RTT109 gene Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101710087237 Whey acidic protein Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/102—Caprine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CUCU2002/0235 | 2002-10-21 | ||
| CU20020235A CU23102A1 (es) | 2002-10-21 | 2002-10-21 | Método para la producción de proteínas recombinantes en la glándula mamaria de mamíferos no transgénicos |
| PCT/CU2003/000011 WO2004034780A2 (es) | 2002-10-21 | 2003-10-20 | Método para la producción de proteínas recombinantes en la glándula mamaria de mamíferos no transgénicos |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2003273726A1 AU2003273726A1 (en) | 2004-05-04 |
| AU2003273726B2 AU2003273726B2 (en) | 2009-07-09 |
| AU2003273726B8 true AU2003273726B8 (en) | 2009-09-03 |
Family
ID=40134844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003273726A Expired - Fee Related AU2003273726B8 (en) | 2002-10-21 | 2003-10-20 | Method of producing recombinant proteins in the mammary gland of non-transgenic mammals |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1557084A2 (ru) |
| JP (1) | JP2006503560A (ru) |
| KR (1) | KR20050083791A (ru) |
| CN (1) | CN1744814A (ru) |
| AR (1) | AR041644A1 (ru) |
| AU (1) | AU2003273726B8 (ru) |
| BR (1) | BR0315555A (ru) |
| CA (1) | CA2502902A1 (ru) |
| CU (1) | CU23102A1 (ru) |
| MX (1) | MXPA05004295A (ru) |
| RU (1) | RU2345088C2 (ru) |
| WO (1) | WO2004034780A2 (ru) |
| ZA (1) | ZA200503166B (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23576A1 (es) * | 2006-02-28 | 2010-09-30 | Ct Ingenieria Genetica Biotech | Antígenos vacunales quiméricos contra el virus de la influenza aviar |
| CU23544A1 (es) * | 2006-02-28 | 2010-06-17 | Ct Ingenieria Genetica Biotech | Antígenos vacunales quiméricos contra el virus de la peste porcina clásica |
| CN1869217B (zh) * | 2006-05-22 | 2013-08-07 | 李青旺 | 以腺病毒为载体乳腺表达生产转基因蛋白药物的方法 |
| US9738694B2 (en) | 2008-06-30 | 2017-08-22 | Cho-A Pharm. Co., Ltd. | Gene of porcine alpha-s1 casein, a promoter of the same and use thereof |
| KR20140132706A (ko) * | 2011-12-19 | 2014-11-18 | 엘에프비 유에스에이, 인크. | 염증성 장애의 치료를 위한 재조합 인간 알파-1-안티트립신 |
| CL2014002410A1 (es) * | 2014-09-12 | 2014-11-14 | Univ Concepcion | Método para la producción de proteínas recombinantes en glándula mamaria de mamíferos mediante la transformación del epítelio glandular mamario con vectores adenoasociados. |
| WO2018085967A1 (en) * | 2016-11-08 | 2018-05-17 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences | Genetically humanized mammals expressing human serum albumin and uses thereof |
| ES2980492T3 (es) | 2019-07-25 | 2024-10-01 | Medichem S A | Procedimiento para la síntesis de N-alquil-4-piridinaminas |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996022379A2 (en) * | 1995-01-20 | 1996-07-25 | Nexia Biotechnologies, Inc. | Direct gene transfer into the ruminant mammary gland |
| WO1999043795A1 (en) * | 1998-02-24 | 1999-09-02 | Her Majesty In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada | Trans-somatics with gene transfer into mammary epithelial cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7719596A (en) * | 1995-11-07 | 1997-05-29 | Baylor College Of Medicine | Adenovirus-mediated production of bioactive proteins by mammalian cells and animals |
| EP0954579A1 (en) * | 1996-06-20 | 1999-11-10 | Merck & Co., Inc. | Gene therapy for obesity |
| WO2002034282A2 (en) * | 2000-10-27 | 2002-05-02 | Beth Israel Deaconess Medical Center, Inc. | Mammary secreted protein 36 (msp36) for cancer treatment and diagnosis |
-
2002
- 2002-10-21 CU CU20020235A patent/CU23102A1/es unknown
-
2003
- 2003-10-16 AR ARP030103775A patent/AR041644A1/es not_active Application Discontinuation
- 2003-10-20 AU AU2003273726A patent/AU2003273726B8/en not_active Expired - Fee Related
- 2003-10-20 MX MXPA05004295A patent/MXPA05004295A/es unknown
- 2003-10-20 CN CNA2003801034448A patent/CN1744814A/zh active Pending
- 2003-10-20 BR BR0315555-2A patent/BR0315555A/pt not_active IP Right Cessation
- 2003-10-20 RU RU2005115495/13A patent/RU2345088C2/ru active
- 2003-10-20 EP EP03757653A patent/EP1557084A2/en not_active Withdrawn
- 2003-10-20 JP JP2004543918A patent/JP2006503560A/ja active Pending
- 2003-10-20 WO PCT/CU2003/000011 patent/WO2004034780A2/es active Application Filing
- 2003-10-20 KR KR1020057006830A patent/KR20050083791A/ko not_active Application Discontinuation
- 2003-10-20 CA CA002502902A patent/CA2502902A1/en not_active Abandoned
-
2005
- 2005-04-19 ZA ZA200503166A patent/ZA200503166B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996022379A2 (en) * | 1995-01-20 | 1996-07-25 | Nexia Biotechnologies, Inc. | Direct gene transfer into the ruminant mammary gland |
| WO1999043795A1 (en) * | 1998-02-24 | 1999-09-02 | Her Majesty In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada | Trans-somatics with gene transfer into mammary epithelial cells |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006503560A (ja) | 2006-02-02 |
| KR20050083791A (ko) | 2005-08-26 |
| AU2003273726B2 (en) | 2009-07-09 |
| RU2005115495A (ru) | 2005-11-20 |
| WO2004034780A3 (es) | 2004-05-27 |
| ZA200503166B (en) | 2006-10-25 |
| RU2345088C2 (ru) | 2009-01-27 |
| CN1744814A (zh) | 2006-03-08 |
| CU23102A1 (es) | 2005-12-20 |
| WO2004034780A2 (es) | 2004-04-29 |
| MXPA05004295A (es) | 2005-08-03 |
| AU2003273726A1 (en) | 2004-05-04 |
| CA2502902A1 (en) | 2004-04-29 |
| BR0315555A (pt) | 2005-08-23 |
| AR041644A1 (es) | 2005-05-26 |
| EP1557084A2 (en) | 2005-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200503166B (en) | Method of producing recombinant proteins in the mammary gland on non-transgenic mammals | |
| JP7128190B2 (ja) | ウィルソン病を処置するための遺伝子療法 | |
| RU2762257C2 (ru) | Генная терапия для лечения гемофилии a | |
| EP0866873B1 (en) | Non-group c adenoviral vectors | |
| JPH08501703A (ja) | 欠陥組換えアデノウイルスベクター及び遺伝子治療での使用 | |
| US7888321B2 (en) | Production of high levels of transgenic factor IX without gene rescue, and its therapeutic uses | |
| Toledo et al. | High expression level of recombinant human erythropoietin in the milk of non-transgenic goats | |
| Sánchez et al. | Adenoviral vector mediates high expression levels of human growth hormone in the milk of mice and goats | |
| JP4386971B2 (ja) | スプライシング配列を含んでなる組換えアデノウイルスベクター | |
| JPH11510049A (ja) | 組換えウイルスベクター製造用ヘルパーウイルス | |
| JP2010528677A (ja) | 乳中に外因性タンパク質を産生するトランスジェニック哺乳動物 | |
| EP1379677A2 (en) | Production of high levels of trangenic factor ix without gene rescue, and its therapeutic uses | |
| EP0771874B1 (en) | Transgenic protein production | |
| US6830929B1 (en) | In vitro construction of SV40 viruses and pseudoviruses | |
| CN1869217B (zh) | 以腺病毒为载体乳腺表达生产转基因蛋白药物的方法 | |
| Xiao et al. | Expression of recombinant human nerve growth factor beta in milk of goats by recombinant replication-defective adenovirus | |
| Xiao et al. | High-level expression of recombinant human nerve growth factor beta in milk of nontransgenic rabbits | |
| Han et al. | Efficient human growth hormone gene expression in the milk of non-transgenic goats | |
| WO2016037297A1 (es) | Método para la producción de proteínas recombinantes en glándula mamaria de mamíferos mediante la transformación del epitelio glandular mamario con vectores adenoasociados | |
| US9920103B2 (en) | Preparation of recombinant human plasma phospholipid transfer protein (PLTP) from the milk of transgenic rabbits | |
| KR20010086357A (ko) | 재조합 ｃｅｌｏ 바이러스 및 ｃｅｌｏ 바이러스 ｄｎａ | |
| Toledo et al. | New procedure for the production of biopharmaceutical proteins in the milk of non-transgenic animals | |
| JPH11510685A (ja) | 可溶性ｃｔｌａ４分子を用いる関心とする遺伝子の発現を延長する方法 | |
| WO2024079667A1 (en) | Nucleic acid regulatory elements for gene expression in the central nervous system and methods of use | |
| Montesino et al. | The mammary gland: bioreactor for the production of recombinant proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK24 | Application lapsed reg. 22.2e(2) - failure to pay response fee | ||
| NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO PAY AN EXAM RESPONSE FEE HAS BEEN EXTENDED TO 03 JUN 2009. |
|
| TH | Corrigenda |
Free format text: IN VOL 23, NO 26, PAGE(S) 9006 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA, APPLICATION NO. 2003273726, UNDER INID (72) CORRECT THE CO-INVENTOR TO RODRIGUEZ MOLTO, MARIA PILAR |
|
| MK25 | Application lapsed reg. 22.2i(2) - failure to pay acceptance fee |